Investigation of new biological markers for prostate cancer in Chinese men
The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population
This study is trying to find new markers to help diagnose and manage prostate cancer better in Chinese men.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Shatin) |
| Trial ID | NCT03893929 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify and validate new biological markers for the diagnosis and management of prostate cancer specifically in the Chinese population. Given the limitations of the current serum PSA marker, which often leads to misdiagnosis and inadequate risk stratification, the study seeks to improve patient outcomes by exploring alternative markers. The research will involve adult Chinese male patients suspected of having prostate cancer based on clinical evaluations. The findings could lead to more accurate diagnoses and tailored treatment strategies for prostate cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adult Chinese males over 18 years old who are clinically suspected of having prostate cancer.
Not a fit: Patients who refuse or are unable to provide consent for the study will not benefit from this research.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and management strategies for prostate cancer in Chinese patients.
How similar studies have performed: Other studies have shown success in identifying new biomarkers for prostate cancer, but this approach is particularly focused on the Chinese population, making it a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult Chinese male patients with age \> 18 years old 2. Clinical suspected to have prostate cancer, based on abnormal digital rectal examination or elevated serum PSA level Exclusion Criteria: 1\. Patient refused or unable to provide consent for the study
Where this trial is running
Shatin
- Prince of Wales Hospital — Shatin, Hong Kong (Recruiting)
Study contacts
- Principal investigator: Chi Fai Ng, MD — Chinese University of Hong Kong
- Study coordinator: Chi Fai Ng, MD
- Email: ngcf@surgery.cuhk.edu.hk
- Phone: 852-3505-1663
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.